Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
HoloMonitor publication highlight 2024
2024 has been an exciting year for us at Phase Holographic Imaging, and we’re thrilled to share some big news: HoloMonitor, our label-free live cell analysis tool, has now been featured in over 300 publications worldwide.
Biostock inverview with acting CEO: ”We aim to drive innovation that accelerates breakthroughs in regenerative medicine”
With the introduction of the HoloMonitor CellSync, Phase Holographic Imaging (PHI) leaps forward in live cell imaging technology. Currently in the final stages of development, this next-generation imaging system is undergoing pre-production testing at prestigious U.S. institutions – the Huntsman Cancer Institute and the Wake Forest Institute of Regenerative Medicine. Biostock has interviewed the acting CEO, Ivan Jurković, to learn more.
Picture-Perfect Science! HoloMonitor® Images Featured on Cover of Advanced Biology
We are proud to announce that a recent study utilizing HoloMonitor® M4 has been featured on the cover of Advanced Biology, Volume 9, Issue 2 (February 2025). The study, led by Dr. Besa Xhabija and colleagues at the University of Michigan-Dearborn, USA, demonstrates the transformative potential of HoloMonitor, our non-invasive, real-time live cell imaging system, in advancing melanoma research.
Interim Report 3 2024/25
Sales grew significantly for both Q3 and YTD, outperforming the FY results of the previous year. Gross margin continues to be strong, even slightly above planned levels (+4pp). Overall costs remain stable and as per plan, with higher administrative costs due to the capital raise offset by lower R&D expenses. The absolute key to transforming the Company, both short-term and long-term, is a significant increase in sales, which is expected due to a strong pipeline and company potential.
Phase Holographic Imaging Announces Next Generation HoloMonitor
Phase Holographic Imaging (PHI) is pleased to announce that the next generation of PHI’s live cell imaging system enters its final development stage. The new model is currently undergoing pre-production testing both internally and externally at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine.
Phase Holographic Imaging Announces Management Changes
Recent technical progress has led the Board of Directors of Phase Holographic Imaging (PHI) to decide to focus resources on the company’s clinical product development program. In relation to this, the Board of Directors has, in discussion with CEO Anders Månsson, decided to initiate the search for a new CEO to lead the ambitious development that lies ahead.
PHI announces last day of trading in BTA
Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ) 8 January 2025
Phase Holographic Imaging PHI AB (publ), held a general meeting on 8 January 2025. The following resolutions were made.
PHI announces outcome of rights issue
Founder and board member subscribes for shares in the ongoing rights issue
Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB has notified the Company that he, together with closely related parties, follows Altium SA’s lead by subscribing for shares in the Company’s ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.